Bio-Techne Corp - Company Profile
Powered by 
All the sales intelligence you need on Bio-Techne Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Bio-Techne Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Bio-Techne Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Bio-Techne Corp (Bio-Techne) is a biotech company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets. Its activities include producing a wide range of biological products and solutions for research and clinical diagnostics. The company’s products include ELISA kits, ELISpot kits, enzymes, Luminex assays, proteins, GMP products and instruments. Bio-Techne's custom service offerings comprise antibody services, targeted protein degradation services, licensing, cell and gene therapy services, compound library services, ELISA services and gene engineering services. It conducts research in the areas of cancer, cardiovascular, cell and gene therapy, COVID-19, glycobiology, immunology, immuno-oncology, metabolism, neuroscience, pharmacology and stem cells. Bio-Techne is headquartered in Minneapolis, Minnesota, the US.
Headquarters
United States of America
Address
614 McKinley Place North East, Minneapolis, Minnesota, 55413
Website
www.bio-techne.com
Telephone
1 612 3792956
No of Employees
3,000
Industry
Medical Equipment
Ticker Symbol & Exchange
TECH (NASD)
Revenue (2025)
$1.2B
5.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-56.3%
(2025 vs 2024)
Market Cap*
$11.4B
Net Profit Margin (2024)
XYZ
-58.5%
(2025 vs 2024)
* As of and is in US$
Bio-Techne Corp premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Reagents and Kits: | Custom | R&D Systems |
| Antibodies | Custom Antibody Services | Novus Biologicals |
| Cell Culture Reagents | Custom Cell and Gene Therapy Services | exosomedx |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Corporate Changes/Expansions | In October, the company opened a new facility in Bristol, the UK, to manufacture Good Manufacturing Practice-grade small molecules. |
| 2026 | Contracts/Agreements | In September, the company signed an agreement to be acquired by Merck KGaA for US$11.3 billion. |
| 2026 | Others | In September, the company secured shareholders' approval to be acquired by Merck KGaA, Darmstadt, Germany. |
Competitor Comparison
| Key Parameters | Bio-Techne Corp | Thermo Fisher Scientific Inc | GE HealthCare Technologies Inc | Agilent Technologies Inc | Waters Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Minneapolis | Waltham | Chicago | Santa Clara | Milford |
| State/Province | Minnesota | Massachusetts | Illinois | California | Massachusetts |
| No. of Employees | 3,000 | 125,000 | 54,000 | 18,200 | 7,900 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kim Kelderman | Director; President; Chief Executive Officer | Executive Board | 2023 | 59 |
| James Hippel | Executive Vice President; Chief Financial Officer | Senior Management | 2014 | 55 |
| Gary Latham | Chief Technology Officer; Vice President | Senior Management | 2023 | - |
| Shane Bohnen | Senior Vice President; Chief Sustainability Officer; General Counsel; Secretary | Senior Management | 2019 | 49 |
| Steven Silverman | Senior Vice President - Customer Experience | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer